Cetuximab in the treatment of metastatic colorectal cancer

Bibliography

• TOURNIGAND C, ANDRE T, ACHILLE E et al.: FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. (2004) 22:229-237.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:23-30.
   PubMed Web of Science ®Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J. Clin. Oncol. (2005) 23(16S):1s, Abstract 2.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. (2001) 19(Suppl. 18):32S-40S.
   PubMed Web of Science ®Google Scholar
• KRAUSE DS, VAN ETTEN RA: Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. (2005) 353:172-187.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21:2787-2799.
   PubMed Web of Science ®Google Scholar
• MIETTINEN PJ, BERGER JE, MENESES J et al.: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature (1995) 376:337-341.
   PubMed Web of Science ®Google Scholar
• THREADGILL DW, DLUGOSZ AA, HANSEN LA et al.: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 269(5221):230-234.
   PubMed Web of Science ®Google Scholar
• NICHOLSON RI, GEE JM, HARPER ME et al.: EGFR and cancer prognosis. Eur. J. Cancer (2001) 37(Suppl. 4):S9-S15.
   PubMedGoogle Scholar
• GOLDSTEIN NI, PREWETT M, ZUKLYS K et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
   PubMed Web of Science ®Google Scholar
• FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3(5):391-400.
   PubMed Web of Science ®Google Scholar
• HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005). 23(5):1011-27.
   PubMed Web of Science ®Google Scholar
• VINCENZI B, SANTINI D, RUSSO A et al.: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann. Oncol. (2006) 17:835-841.
   PubMed Web of Science ®Google Scholar
• VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. (2005) 23:3536-3544.
   PubMed Web of Science ®Google Scholar
• DELBALDO C, PIERGA JY, DIERAS V et al.: Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer (2005) 41(12):1739-1745.
   PubMed Web of Science ®Google Scholar
• TABERNERO J, CERVANTES A, MARTINELLI E et al.: Optimal dose of cetuximab given every 2 weeks (q2w): a Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. (2006) 24(18S):142s, Abstract 3085.
   Google Scholar
• PREWETT MC, HOOPER AT, BASSI R et al.: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. (2002) 8:994-1003.
   PubMed Web of Science ®Google Scholar
• LIANG K, ANG KK, MILAS L et al.: The epidermal growth factor receptor mediates radioresistance. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57:246-254.
   PubMed Web of Science ®Google Scholar
• BONNER JA, RAISCH KP, TRUMMELL HQ et al.: Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. (2000) 18(21 Suppl.):47S-53S.
   PubMed Web of Science ®Google Scholar
• HUANG SM, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
   PubMed Web of Science ®Google Scholar
• BONNER JA, BUCHSBAUM DJ, RUSSO SM et al.: Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(2 Suppl.):2-10.
   PubMed Web of Science ®Google Scholar
• ROSENBERG AH, LOEHRER PJ, NEEDLE MN et al.: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2002) 21:134a, Abstract 536.
   Google Scholar
• FOLPRECHT G, LUTZ MP, SCHOFFSKI P et al.: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. (2006) 17(3):450-456.
   PubMed Web of Science ®Google Scholar
• PEETERS M, RAOUL JL, VAN LAETHEM JL et al.: Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). ECCO Annual Meeting (2005) Abstract 664.
   Google Scholar
• VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) +/- cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J. Clin. Oncol. (2006) 24(18S):148s, Abstract 3509.
   Google Scholar
• HEINEMANN V, FISCHER VON WEIKERSTHAL L et al.: Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first-line therapy for patients with metastatic colorectal cancer (CRC): preliminary results of a randomised Phase II trial of the AIO CRC Study Group. J. Clin. Oncol. (2006) 24(18S):158s, Abstract 3550.
   Google Scholar
• DIAZ-RUBIO E, TABERNERO J, VAN CUTSEM E et al.: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): an international Phase II study. J. Clin. Oncol. (2005) 23(16S):254s, Abstract 3535.
   PubMed Web of Science ®Google Scholar
• DITTRICH C, HOEHLER T, LORDICK F et al.: A Phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC). Preliminary results. World Congress on Gastrointestinal Cancer (WCGI) (2006) Abstract O-019.
   Google Scholar
• COLUCCI G, GIULIANI F, MATTIOLI R et al.: FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2402). J. Clin. Oncol. (2006) 24(18S):160s, Abstract 3559.
   PubMed Web of Science ®Google Scholar
• DAKHIL S, COSGRIFF T, HEADLEY D et al.: Cetuximab plus FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002). J. Clin. Oncol. (2006) 24(18S):160s, Abstract 3557.
   PubMed Web of Science ®Google Scholar
• BORNER M, MINGRONE W, KOEBERLE D et al.: The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. (2006) 24(18S):158s, Abstract 3551.
   Google Scholar
• LANG I, ZALUSKI J, CHANGCHEIN CR et al.: Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). Preliminary safety results (CRYSTAL). J. Clin. Oncol. (2006) 24(18S):159s, Abstract 3555.
   Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
   PubMed Web of Science ®Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001) 20:2a, Abstract 7.
   Google Scholar
• SALTZ LB, MEROPOL NJ, LOEHRER PJ et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1208.
   PubMed Web of Science ®Google Scholar
• WILKE H, GLYNNE-JONES R, THALER J et al.: MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. J. Clin. Oncol. (2006) 24(18S):158s, Abstract 3549.
   Google Scholar
• SOUGLAKOS J, KALYKAKI A, VAMVAKAS L et al.: Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann. Oncol. (2006) (In Press).
   PubMedGoogle Scholar
• LENZ HJ, MAYER RJ, MIRTSCHING B et al.: Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(16S):255s: Abstract 3536.
   Google Scholar
• ABUBAKR Y, ENG C, WONG L et al.: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 800 patients in a randomized Phase III trial (EPIC). J. Clin. Oncol. (2006) 24(18S):160s, Abstract 3556.
   PubMed Web of Science ®Google Scholar
• SALTZ L, LENZ HJ, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J. Clin. Oncol. (2005) 23(16S):248s, Abstract 3508.
   Google Scholar
• SAUER R, BECKER H, HOHENBERGER W et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. (2004) 351:1731-1740.
   PubMed Web of Science ®Google Scholar
• RODEL C, GRABENBAUER GG, PAPADOPOULOS T et al.: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J. Clin. Oncol. (2003) 21:3098-3104.
   PubMed Web of Science ®Google Scholar
• RYAN DP, NIEDZWIECKI D, HOLLIS D et al.: Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J. Clin. Oncol. (2006) 24:2557-2562.
   PubMed Web of Science ®Google Scholar
• BONNER JA., HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354(6):567-578.
   PubMed Web of Science ®Google Scholar
• MACHIELS JP, SEMPOUX C, SCALLIET P et al.: Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. J. Clin. Oncol. (2006) 24(18S):159s, Abstract 3552.
   Google Scholar
• CHUNG KY, MINSKY B, SCHRAG D et al.: A pilot trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with locally-advanced rectal cancer. J. Clin. Oncol. (2006) 24(18S):161s, Abstract 3560.
   Web of Science ®Google Scholar
• ARNOLD D, HIPP M, REESE T et al.: Phase I/II study of cetuximab, capecitabine, and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). J. Clin. Oncol. (2006) 24(18S):164s, Abstract 3574.
   Google Scholar
• PEREZ-SOLER R, SALTZ L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. (2005) 23:5235-5246.
   PubMed Web of Science ®Google Scholar
• SEGAERT S, TABERNERO J, CHOSIDOW O et al.: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch Dermatol. Ges. (2005) 3:599-606.
   PubMedGoogle Scholar
• SEGAERT S, VAN CUTSEM E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. (2005) 16:1425-1433.
   PubMed Web of Science ®Google Scholar
• ROBERT C, SORIA JC, SPATZ A et al.: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. (2005) 6:491-500.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, DELORD JP, HALPERN A et al.: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 10:345-356.
   PubMed Web of Science ®Google Scholar
• DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041-1047.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
   PubMed Web of Science ®Google Scholar
• KOHNE CH, VAN CUTSEM E, WILS J et al.: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol. (2005) 23:4856-4865.
   PubMed Web of Science ®Google Scholar
• SCHRAG D, CHUNG KY, FLOMBAUM C, SALTZ L: Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. (2005) 97(16):1221-1224.
   PubMed Web of Science ®Google Scholar
• CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23:1803-1810.
   PubMed Web of Science ®Google Scholar
• LENZ, HJ, MAYER RJ, GOLD PJ et al.: Activity of cetuximab in patients with metastatic colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. (2004) 23:248, Abstract 3510.
   Google Scholar
• FRANCOUAL M, ETIENNE-GRIMALDI MC, FORMENTO JL et al.: EGFR in colorectal cancer: more than a simple receptor. Ann. Oncol. (2006) 17:962-967.
   PubMed Web of Science ®Google Scholar
• LIEVRE A, BACHET JB, LE CORRE D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006). 66(8):3992-3995.
   PubMed Web of Science ®Google Scholar
• MORONI M, VERONESE S, BENVENUTI S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. (2005) 6(5):279-286.
   PubMed Web of Science ®Google Scholar
• SALTZ L, KIES MS, ABBRUZZESE JL et al.: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 22:204, Abstract 817.
   Web of Science ®Google Scholar
• TEJPAR S, PEETERS M, HUMBLET Y et al.: Dose-escalating study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. J. Clin. Oncol. (2006) 24(18S):159s, Abstract 3554.
   Google Scholar
• FOLPRECHT G, GROTHEY A, ALBERTS S et al.: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. (2005) 16(8):1311-1319.
   PubMed Web of Science ®Google Scholar
• ADAM R: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol. (2003) 14(Suppl. 2):ii13-ii16.
   PubMed Web of Science ®Google Scholar